Skip to main content

Advertisement

Table 3 Summary of included reviews that investigated modifiable factors

From: Pragmatic methods for reviewing exceptionally large bodies of evidence: systematic mapping review and overview of systematic reviews using lung cancer survival as an exemplar

Author, year REV ID Country Search year* DB RM CH QA Synthesis PR theme No. PFs evaluated** LC type No. of studies Sample size range Included UVA or MVA
Aboshi, 2014 182 Japan 2012 N N Y N MR 2, 4 13 NSCLC (late) 65 NS NS
Ashworth, 2013 237 UK 2012 Y Y P N Narrative 1, 2 Any (total NS) NSCLC (oligometastatic) 49 (23 in analysis of PFs) NS (1064 in analysis of PFs) MVA
Ashworth, 2014 105 UK 2012 Y Y Y N MR 1, 2, 3 20 NSCLC (oligometastatic) 20 6–262 Both
Behera, 2016 5815 US 2015 Y N Y N MA 2 2 NSCLC (I) 19 (11 survival) 8–110 NS
Berghmans, 2011 8434 Belgium 2009 N N P N Narrative 2 Any (> 50) NSCLC (III) 39 42–2048 MVA
Brundage, 2002 1051 Canada 2001 N N N N Narrative 2 Any (169) NSCLC 887 31–1281 MVA
Buttigliero, 2011 494 Italy 2007 Y Y Y Y Narrative 2 2 mxdC (LC/NSCLC) 25 (2 LC) 294–447 MVA
Carter, 2014 5362 US 2010 Y P N Y Narrative 2, 4 12 NSCLC (III–IV) 54 NS MVA
Christopoulos, 2013 5789 Greece 2013 Y Y N N Narrative 2 1 LC 17 4–56 (NS for 3 studies) NS
Deghaidy, 2005 923 Egypt 2004 N Y N N MA 2 1 LC (NSCLC/SCLC) 29 23–1342 NS
Florou, 2014 51 Greece 2013 Y N Y N Narrative 2, 4 1 mxdC NSCLC (early)/SCLC (limited) 20 (13 LC; 4 survival only) 66–2258 NS
Montazeri, 2009 703 Iran 2008 Y N Y N Narrative 2 1 mxdC NSCLC/SCLC 104 (26 LC) 30–651 MVA
Neal, 2015 8441 UK 2013 Y Y Y Y Narrative 2 15 mxdC (LC/NSCLC) 209 (20 LC) 103–566 NS
Olsson, 2009 722 US 2007 Y Y Y Y Narrative 2 1 LC 18 NS (2 studies with > 1000 pts) Both
Parsons, 2010 695 UK 2008 Y Y Y Y MA 1, 2 1 LC (NSCLC/SCLC) 10 61–611 Both
Prades, 2015 5807 Spain 2012 N Y Y N Narrative 2 1 mxdC LC (LC/NSCLC) 51 (3 LC; 1 survival) NS NS
Salah, 2012 467 Jordan 2010 (IS) Y U Y N MR 2 8 NSCLC (isolated met) 51 NS (total 62) Both
Slatore, 2010 621 US 2008 Y P Y Y Narrative 2 1 LC (LC/NSCLC) 23 (9 survival) 249–693,697 Both
von Meyenfeldt, 2012 414 Netherlands 2011 Y Y P N MR 2 3 LC 19 987–90,088 MVA
Yu, 2015 5489 China 2014 Y U N Y MA 2 1 NSCLC 10 21–412 Yes
  1. *Where the search dates were not reported, this was based on the latest publication year of included studies (IS)
  2. **Three reviews, which evaluated ‘any’ prognostic factor included a minimum of 50 factors: Ashworth, 2013 (237); Berghmans, 2011 (8434); and Brundage, 2002 (1051)
  3. REV ID review unique identification number, DB searched more than one reference database searched, No. number, RM used explicit and reproducible methodology used, CH a systematic presentation of the characteristics of included studies presented, QA assessment for the validity of the findings of the included studies conducted, ADC adenocarcinoma, CTX chemotherapy, IS included studies, LC lung cancer, MA meta-analysis, met metastasis, MR meta-regression, MVA multivariate analysis, mxdC mixed cancer, NS not stated, N no, NSCLC non-small cell lung cancer, PF prognostic factor, PR prognostic research, RT radiotherapy, SCC squamous cell carcinoma, SCLC small cell lung cancer, surR surgical resection, sync synchronous, UVA univariate analysis, Y yes